DDInter622 DDInter1676
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Edrophonium {u} (Compound) resembles {v} (Compound) Metaraminol
Edrophonium {u} (Compound) resembles {v} (Compound) Tapentadol
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neostigmine
Edrophonium {u} (Compound) binds {v} (Gene) BCHE
Edrophonium {u} (Compound) upregulates {v} (Gene) IL1R2
Edrophonium {u} (Compound) downregulates {v} (Gene) MAP7
Edrophonium {u} (Compound) causes {v} (Side Effect) Conjunctival hyperaemia
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pyridostigmine
Edrophonium (Compound) resembles Metaraminol (Compound)
Edrophonium (Compound) resembles Tapentadol (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Edrophonium (Compound) binds BCHE (Gene)
Edrophonium (Compound) upregulates IL1R2 (Gene)
Edrophonium (Compound) downregulates MAP7 (Gene)
Edrophonium (Compound) causes Conjunctival hyperaemia (Side Effect)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine